4//SEC Filing
MISSLING CHRISTOPHER U 4
Accession 0001731122-25-000654
CIK 0001314052other
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 8:00 PM ET
Size
5.7 KB
Accession
0001731122-25-000654
Insider Transaction Report
Form 4
MISSLING CHRISTOPHER U
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-04-28+125,000→ 125,000 totalExercise: $8.57From: 2025-04-28Exp: 2033-03-31→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.
Documents
Issuer
ANAVEX LIFE SCIENCES CORP.
CIK 0001314052
Entity typeother
Related Parties
1- filerCIK 0001196573
Filing Metadata
- Form type
- 4
- Filed
- Apr 29, 8:00 PM ET
- Accepted
- Apr 30, 8:00 PM ET
- Size
- 5.7 KB